Vilka är öppettiderna?

Måndag 08:00 - 17:00 Tisdag 08:00 - 17:00 Onsdag 08:00 - 17:00 Torsdag 08:00 - 17:00 Fredag 08:00 - 17:00

Alzecure

Hem
Sverige
Huddinge
Alzecure

Alzecure is a non-profit research foundation with funding initially from donations and grants from individuals, non-profit organizations and governments.

AlzeCure develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The objective of Alzecure Foundation is to enhance scientific research in age related diseases, primarily Alzheimer’s disease and other neurodegenerativ

e conditions, with the aim to develop new therapies, diagnostics, treatments and medical technologies. We develop innovative therapies for the treatment of Alzheimer ́s disease and related neurodegenerative disorders, as well as unique medical technologies that will enable us to detect and monitor treatment effect in patients. This organization form provides stability for continuous evaluation of novel concepts from academic research, but is combined with the overall aim of AlzeCure to commercialize its successful projects. Promising projects will be spun-out as commercial companies, subsidiaries to Alzecure, allowing external partners and investors to buy-in, contribute and collaborate

20/05/2026

BioStock Panel on the Development in the Alzheimer’s Field
- AlzeCure, Alzinova & BioArctic

I was pleased to be invited to Market Signal, BioStock’s studio program about Nordic life science, to discuss the current development in the Alzheimer's field, together with Alzinova’s CEO Tord Labuda and BioArctic’s CFO, Anders Martin-Löf.

The episode airs on Wednesday morning on BioStock, tune in!

See the panel discussion at BioStock: https/biostock.se

Martin JönssonStiftelsen Flemingsberg Science BioArctic Alzinova AB Tord Labuda
Anders Martin-Löf Cecilia Hallström, PhD Jonas Söderström

20/05/2026

AlzeCure Pain Seminar on TrkA-NAM for Osteoarthritis
- Tuesday May 26, 14:00 CEST

AlzeCure Pharma will host a live online seminar on 26 May from 14:00 to 15:00 CEST focusing on ACD137, the leading drug candidate in the TrkA-NAM pain project.

The company recently published new results* for the TrkA-NAM pain project ACD137, and the purpose of the presentations is to explain the background and opportunities for ACD137. This includes pain indications such as osteoarthritis and chemotherapy-induced neuropathic pain, areas with significant unmet medical needs.
- The presentations will be followed by a Q&A session where participants can submit questions.

The presenters from AlzeCure are Martin Jönsson (CEO), Dr. Märta Segerdahl (Chief Medical Officer), and Dr. Pontus Forsell (Head of Discovery & Research).

Hosted in collaboration with Finwire, the event requires no prior registration and can be followed via:
https://www.finwire.tv/webcast/alzecure-pharma/new-data-in-novel-pain-project-trka-nam-against-osteoartritis/
The presentations will be conducted in English and will also be available for later viewing on AlzeCure’s website: https://www.alzecurepharma.se/en/presentations-and-interviews/

AGENDA:

14:00 Introduction to AlzeCure Pharma and project status – Martin Jönsson, CEO

14:05 TrkA-NAM in pain – Major unmet medical needs & indication areas – Dr. Märta Segerdahl, CMO

14:20 TrkA-NAM – Next-generation non-opioid analgesics – Dr. Pontus Forsell, Head of Discovery & Research

14:40 Q&A – Martin Westerlund, moderator FinWire

14:55 Concluding Remarks – Martin Jönsson

New publication on TrkA-NAM - Forsell P, et al. Scand J Pain. 2026 Apr 27;26(1). https://www.degruyterbrill.com/document/doi/10.1515/sjpain-2026-0007/html

AlzeCure Pharma Pontus Forsell Martin Jönsson Märta Segerdahl Finwire Media

14/05/2026

AlzeCure Presents at ABG Investor Day
- May 21 - Come & Join - Welcome 🫵 🫵

AlzeCure Pharma has been invited to present live at ABG Investor Day May 21, at 13:45 CET.

Our CEO Martin Jönsson will share insights into the company's innovative Alzheimer's and pain pipeline and ongoing development in pain projects and in the Q&A he will be joined by AlzeCure’s Chief Scientific Officer Johan Sandin.

🔗 See us live: cr.abgsc.com

You also have the opportunity to apply to participate in person at the event in Stockholm City, at Hotel At Six Brunkebergstorg 6: https://cr.abgsc.com/artiklar/2026/03/event-registration---abgsc-investor-days-seminar-21-22-may-stockholm/

Afterwards the presentation will be published at our website under interviews and presentations: https://www.alzecurepharma.se/en/presentations-and-interviews/

To the press release: https://www.alzecurepharma.se/en/alzecure-pharma-to-present-at-abg-investor-days-on-may-21/

Avanza Bank Nordnet Bank AB AlzeCure Pharma Martin Jönsson ABG Sundal Collier Life Science Cluster Flemingsberg Stiftelsen Flemingsberg Science

13/05/2026

AlzeCure Presents at Redeye Investor Forum
- May 21 - Welcome 🫵 🫵

AlzeCure Pharma has been invited to present live at Redeye Investor Forum event on May 21 at 15:20 CET.

Our CEO Martin Jönsson will share insights into the company's innovative Alzheimer's and pain pipeline and ongoing development in pain projects and in the Q&A he will be joined by AlzeCure’s Chief Scientific Officer Johan Sandin.

🔗 See us live: https://www.redeye.se/events/1143980/investor-forum-online-41

Afterwards the presentation will be published at our website inter interviews and presentations: https://www.alzecurepharma.se/en/presentations-and-interviews/

To the press release: https://www.alzecurepharma.se/en/alzecure-pharma-to-present-at-redeye-investor-forum-online-on-may-21/

Johan Sandin Martin Jönsson AlzeCure Pharma Redeye Group Life Science Cluster Flemingsberg Stiftelsen Flemingsberg Science

11/05/2026

Intervju med AlzeCures vd Martin Jönsson om bolagets senaste kvartalsrapport, utveckling samt planer.

Intervjun genomfördes av FinWire i samband med att AlzeCure Pharma släppte sin senaste kvartalsrapport den 5 maj 2026.

Se intervjun här: https://youtu.be/pF-uUQCe1VQ

Till pressreleasen om kvartalsrapporten: https://www.alzecurepharma.se/sv/alzecure-offentliggor-delarsrapport-for-januari-mars-2026/

07/05/2026

AlzeCure Pharma published Q1 2026 report.

Continued positive development

“During the first quarter of 2026, our focus was on preparing the Phase II study in Alzheimer’s patients with NeuroRestore ACD856, for which we were awarded a grant of EUR 2.5 million from the European Innovation Council (EIC). In addition, we successfully advanced the Phase Ib clinical trial with ACD856, further expanding the therapeutic dose window to increase our opportunities to address multiple indications. During the quarter, we also continued preparing for a potential registrational study for the pain project Painless ACD440. In February, ACD440 was granted orphan drug designation by the European Medicines Agency. We also remained active in business development at international conferences and published new data from our NeuroRestore project at the world-leading Alzheimer’s conference AD/PD 2026, which was held in Copenhagen in March.” – Martin Jönsson, CEO

Significant events during the period January – March 2026

In February 2026, the pain project ACD440 was granted orphan drug designation in Europe by the EMA.

AlzeCure presented new preclinical data concerning NeuroRestore ACD856 at the AD/PD Alzheimer’s conference in mid-March.

Significant events after the end of the period

In April, the company announces that the last participant has completed treatment in AlzeCure's clinical phase Ib study with NeuroRestore ACD856.
In April, the board of directors, supported by the authorization granted by the Annual General Meeting on May 14, 2025, decides to carry out a rights issue of approximately SEK 30.1 million. The issue is, free of charge, 100 percent secured.

Read the full report here:https://www.alzecurepharma.se/en/wp-content/uploads/sites/2/2026/04/alzecure-q1-2026-eng-final-260505.pdf

AlzeCure Pharma Life Science Cluster Flemingsberg

07/05/2026

New AlzeCure publication on our pain project TrkA-NAM targeting osteoarthritis

Our article on the analgesic and knee joint protective effects of TrkA-NAM ACD137 in a model of osteoarthritis is now available online. In moments like this, I miss paper reprints, so I settled for this AI-generated 'happy scientist figure' with a virtual preprint.

TrkA-NAM ACD137 is a highly potent and selective negative allosteric modulator of TrkA for the treatment of pain.

The on-line version can be found using the link below: https://www.degruyterbrill.com/document/doi/10.1515/sjpain-2026-0007/html

Pontus Forsell Märta Segerdahl Johan Sandin Maria Backlund Cristina Parrado Veronica Lidell Gunnar Nordvall AlzeCure Pharma Life Science Cluster Flemingsberg

28/04/2026

Intervju om AlzeCures förestående företrädesemission under maj 2026

Intervju hos Redeye av analytikern Filip Lindkvist med AlzeCures vd Martin Jönsson om den förestående företrädesemissionen som AlzeCure kommer genomföra under maj 2026 vilken redan är säkrad till 100%, utan ersättning till externa parter. Bolaget planerar att ta in drygt 30,1 MSEK

Se intervjun här: https://www.youtube.com/watch?v=CyDLQ4EdVGU

Till pressreleasen om emissionen: https://www.alzecurepharma.se/sv/disclaimer/?redirect=https://www.alzecurepharma.se/sv/alzecure-pharma-genomfor-en-till-100-procent-sakerstalld-foretradesemission-om-ca-301-msek/

24/04/2026

AlzeCure Pharma carries out a fully secured rights issue of approximately SEK 30.1 million

AlzeCure today announced that the Board of Directors has resolved on a new share issue of approximately SEK 30.1 million, in a coming rights issue, which is secured to 100%, without cost for the Company.

AlzeCure is currently engaged in active and concrete discussions with several external parties regarding potential licensing and collaboration agreements for the Company's drug candidates. The Rights Issue is carried out to strengthen the cash position and provide resources for business development, pending these discussions.

The Rights Issue is fully secured to 100 percent as the Company's two major shareholders, BWG Invest Sàrl and Sjuenda Holding AB, have undertaken, free of charge, to subscribe for all shares not subscribed for by other shareholders or subscription rights holders. Subscription undertakings from the Company's two major shareholders, Board of Directors, management and other larger shareholders amount to approximately SEK 9.3 million, corresponding to approximately 31 percent of the Rights Issue.

"We are very pleased that our major shareholders, as well as all members of the Board of Directors, support our projects by committing to subscribe for their respective pro-rata shares in the Rights Issue. The Company is now at a stage where business development is critical to realizing the value inherent in the project portfolio. The Company is engaged in active discussions with several parties regarding potential licensing and collaboration agreements, and through this share issue the cash position is strengthened to intensify out-licensing efforts and capitalize on the opportunities being discussed. The strong support from existing shareholders means that the transaction is, free of charge, 100% secured, which is very positive," says Martin Jönsson, CEO of AlzeCure Pharma AB.

The subscription price is SEK 1.31 per share.

Read the full press release here: https://www.alzecurepharma.se/en/alzecure-pharma-carries-out-a-fully-secured-rights-issue-of-approximately-sek-30-1-million/

AlzeCure Pharma ABG Sundal CollierLife Science Cluster Flemingsberg Stiftelsen Flemingsberg Science Martin JönssonAlzheimerfonden

24/04/2026

AlzeCure Pharma genomför en till 100 procent säkerställd företrädesemission om ca 30,1 MSEK

AlzeCure meddelade idag att styrelsen har beslutat att genomföra en företrädesemission om cirka 30,1 MSEK vilken är till 100% säkerställd till utan kostnad för bolaget, dvs ingen ersättning för att teckna i emissionen kommer att betalas.

AlzeCure för idag aktiva och konkreta samtal med flera externa aktörer kring möjliga licens- och samarbetsaffärer avseende bolagets läkemedelskandidater. Företrädesemissionen genomförs för att stärka kassan och ge resurser till affärsutveckling, i avvaktan på dessa samtal.

Företrädesemissionen är till 100 procent säkerställd genom att Bolagets två huvudägare, BWG Invest Sàrl och Sjuenda Holding AB, vederlagsfritt, förbinder sig att teckna samtliga aktier som inte tecknas av andra aktieägare eller teckningsberättigade.

Teckningsförbindelser från Bolagets två huvudägare, styrelse, ledning och andra större aktieägare uppgår till cirka 9,3 MSEK, motsvarande cirka 31 procent av Företrädesemissionen.

”Det är mycket glädjande att våra större ägare, såväl som samtliga styrelsemedlemmar stödjer våra projekt genom att förbinda sig att teckna sina respektive andelar av Företrädesemissionen. Bolaget befinner sig nu i en fas där affärsutveckling är avgörande för att realisera det värde som finns i projektportföljen. Bolaget för aktiva
diskussioner med flera aktörer om eventuella licens- och samarbetsaffärer och genom denna emission stärks kassan för att kunna intensifiera utlicensieringsarbetet och utnyttja de möjligheter som diskuteras. Det starka stödet av existerande ägare gör att transaktionen, vederlagsfritt, är 100% säkerställd, vilket känns mycket positivt,” säger Martin Jönsson, VD på AlzeCure Pharma AB.

Teckningskursen är satt till 1,31 SEK.

Läs den fullständiga pressreleasen här: https://www.alzecurepharma.se/sv/disclaimer/?redirect=https://www.alzecurepharma.se/sv/alzecure-pharma-genomfor-en-till-100-procent-sakerstalld-foretradesemission-om-ca-301-msek/

AlzeCure Pharma ABG Sundal Collier Life Science Cluster Flemingsberg Stiftelsen Flemingsberg Science Martin Jönsson

Adress

Hälsovägen 7
Huddinge
14157

Öppettider

Måndag	08:00 - 17:00
Tisdag	08:00 - 17:00
Onsdag	08:00 - 17:00
Torsdag	08:00 - 17:00
Fredag	08:00 - 17:00

Telefon

+46704979724

Webbplats

http://www.alzecure.org/, https://www.alzecurepharma.se/en/subscribe-media/, https://www.alzecurepharma.se/sv/prenumerer

Aviseringar

Var den första att veta och låt oss skicka ett mail när Alzecure postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Kontakta Praktiken

Skicka ett meddelande till Alzecure:

Genvägar

Vill du placera din praktik längst upp i Klinik-listan i Huddinge?

Dela

Typ

Medicinskt labb